Clinical Trial Design: Statistical Options/Challenges Panel Discussion

First International Summit on Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Peter Clark, MA, MD, FRCP: A Payer Perspective

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Leonard B. Saltz, MD, of Memorial Sloan Kettering Cancer Center, discusses interventional pharmacoeconomics as an important tool that can offer patients with cancer more efficacious and cost-effective care. Pharmacoeconomics may help reduce the high costs of cancer therapy, with evidence-based reductions in doses that maintain effective treatment.

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Oct

Today In Oncology

Clinical Trial Design: Statistical Options/Challenges Panel Discussion

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Peter Clark, MA, MD, FRCP: A Payer Perspective

Leonard B. Saltz, MD, on Interventional Pharmacoeconomics: A Pathway to Better Cancer Care

Deborah Collyar: What's In It for Patients?

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Final MINT Study Results Strengthen Real-World Evidence for Mogamulizumab in Mycosis Fungoides and Sezary Syndrome

FDA Grants Traditional Approval to Pembrolizumab for TMB-H Solid Tumors

Geographic Distribution of Triple-Negative Breast Cancer Clinical Trials

Financial Incentives Increase Smoking Abstinence Among Those Referred for Lung Cancer Screening

Metastasis-Directed Ablation Does Not Improve Survival Outcomes in Oligometastatic Breast Cancer